Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:04:10 EDT Sat 12 Jul 2025
Enter Symbol
or Name
USA
CA



Q:SPRY - ARS PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SPRY - Q0.810.55·18.090.117.69-0.29-1.61,113.019,13710,13617.98  18.045  17.4618.89  8.905518:40:33May 2715 min RT 2¢

Recent Trades - Last 10 of 10136
Time ETExPriceChangeVolume
18:40:33Q17.69-0.2910
18:23:01Q17.68-0.302
16:20:00Q17.69-0.29442
16:11:52Q17.69-0.299,338
16:04:15Q17.69-0.291
16:04:15Q17.69-0.291
16:04:10Q17.69-0.291
16:04:05Q17.69-0.291
16:02:17Q17.69-0.29246
16:02:17Q17.69-0.29142

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-05-27 08:01U:SPRYNews ReleaseARS Pharmaceuticals to Participate in Upcoming Investor Conferences
2025-05-14 07:00U:SPRYNews ReleaseARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy(TM) (epinephrine nasal spray)
2025-05-07 08:00U:SPRYNews ReleaseARS Pharmaceuticals' neffy(TM) (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
2025-05-05 08:00U:SPRYNews ReleaseARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
2025-05-02 08:00U:SPRYNews ReleaseARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abello A/S to Expand Reach of neffy(TM) (epinephrine nasal spray) to Additional U.S. Pediatricians
2025-03-20 07:00U:SPRYNews ReleaseARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
2025-03-05 16:10U:SPRYNews ReleaseARS Pharmaceuticals Announces FDA Approval of neffy(TM) 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
2025-03-03 16:35U:SPRYNews ReleaseARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
2025-02-20 19:02U:SPRYNews ReleaseARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy(TM) (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
2025-02-18 08:00U:SPRYNews ReleaseARS Pharmaceuticals to Showcase Innovation and Present Data on neffy(TM) (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
2025-02-05 08:00U:SPRYNews ReleaseARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
2025-01-21 08:00U:SPRYNews ReleaseARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools
2025-01-13 08:00U:SPRYNews ReleaseARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy(TM) (epinephrine nasal spray)
2025-01-06 08:00U:SPRYNews ReleaseARS Pharmaceuticals Files for Approval of neffy(TM) in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abello A/S
2024-12-19 17:25U:SPRYNews ReleaseARS Pharmaceuticals Announces neffy(TM) (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
2024-12-18 08:00U:SPRYNews ReleaseARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-12 14:33U:SPRYNews ReleaseARS Pharmaceuticals Announces Filings for Approval of neffy(TM) in China, Japan and Australia
2024-12-04 08:00U:SPRYNews ReleaseARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
2024-11-13 06:30U:SPRYNews ReleaseARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
2024-11-11 07:00U:SPRYNews ReleaseARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy(TM) in Europe, Canada and Other Geographies Outside the United States